Continued expansion of Adcetris' indications and pipeline progress support a positive moat trend.
Following Seattle Genetics' third-quarter earnings, we are increasing our fair value estimate to $47 per share from $43. Our updated valuation is largely driven by the progression of Seattle Genetics’ in-house and partnered pipeline, and to a lesser extent, slightly more optimistic expectations for Adcetris in frontline Hodgkin lymphoma and the time value of money. We also adjusted our 2017 revenue and research and development projections to reflect management’s more favorable full-year guidance...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.